Performance of a transcription-mediated-amplification HIV-1 RNA assay in pooled specimens

Nicola M. Zetola; Ann Mintie; Sally Liska; Ernest Wong; Joan Dunn Williams; Michael P. Busch; Jeffrey D. Klausner

doi:10.1016/j.jcv.2007.06.004

Performance of a transcription-mediated-amplification HIV-1 RNA assay in pooled specimens

Nicola M. Zetola, Ann Mintie, Sally Liska, Ernest Wong, Joan Dunn Williams, Michael P. Busch, Jeffrey D. Klausner

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background: Very limited data exist on the comparative performance of nucleic acid amplification tests (NATs) for the screening of pooled specimens for acute human immunodeficiency virus (HIV) infection. Study design: In this study, we compared a transcription-mediated-amplification assay (Procleix^® HIV-1 Discriminatory Assay, [TMA]) with a branched DNA assay (Bayer Versant HIV-1 RNA 3.0 assay, [bDNA]). Results: After re-testing 1552 samples that were negative for HIV RNA by bDNA, we found one additional positive sample with the TMA assay. Conclusion: Our results suggest that TMA could potentially detect acute HIV infections missed by other technologies.

Original language	English (US)
Pages (from-to)	68-70
Number of pages	3
Journal	Journal of Clinical Virology
Volume	40
Issue number	1
DOIs	https://doi.org/10.1016/j.jcv.2007.06.004
State	Published - Sep 2007
Externally published	Yes

Keywords

bDNA
HIV
Pooled testing
TMA

ASJC Scopus subject areas

Virology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jcv.2007.06.004

Cite this

@article{ab6e91ad95b74472bac4db2dffb92731,

title = "Performance of a transcription-mediated-amplification HIV-1 RNA assay in pooled specimens",

abstract = "Background: Very limited data exist on the comparative performance of nucleic acid amplification tests (NATs) for the screening of pooled specimens for acute human immunodeficiency virus (HIV) infection. Study design: In this study, we compared a transcription-mediated-amplification assay (Procleix{\textregistered} HIV-1 Discriminatory Assay, [TMA]) with a branched DNA assay (Bayer Versant HIV-1 RNA 3.0 assay, [bDNA]). Results: After re-testing 1552 samples that were negative for HIV RNA by bDNA, we found one additional positive sample with the TMA assay. Conclusion: Our results suggest that TMA could potentially detect acute HIV infections missed by other technologies.",

keywords = "bDNA, HIV, Pooled testing, TMA",

author = "Zetola, {Nicola M.} and Ann Mintie and Sally Liska and Ernest Wong and Williams, {Joan Dunn} and Busch, {Michael P.} and Klausner, {Jeffrey D.}",

note = "Funding Information: Financial Support: This project was supported in part by the Universitywide AIDS Research Program grant CH05-SMCHC-612 and the San Francisco Department of Public Health. Gen-Probe, Inc. supplied reagents for HIV Procleix HIV-1 Discriminatory RNA testing at no cost to the study.",

year = "2007",

month = sep,

doi = "10.1016/j.jcv.2007.06.004",

language = "English (US)",

volume = "40",

pages = "68--70",

journal = "Journal of Clinical Virology",

issn = "1386-6532",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Performance of a transcription-mediated-amplification HIV-1 RNA assay in pooled specimens

AU - Zetola, Nicola M.

AU - Mintie, Ann

AU - Liska, Sally

AU - Wong, Ernest

AU - Williams, Joan Dunn

AU - Busch, Michael P.

AU - Klausner, Jeffrey D.

N1 - Funding Information: Financial Support: This project was supported in part by the Universitywide AIDS Research Program grant CH05-SMCHC-612 and the San Francisco Department of Public Health. Gen-Probe, Inc. supplied reagents for HIV Procleix HIV-1 Discriminatory RNA testing at no cost to the study.

PY - 2007/9

Y1 - 2007/9

N2 - Background: Very limited data exist on the comparative performance of nucleic acid amplification tests (NATs) for the screening of pooled specimens for acute human immunodeficiency virus (HIV) infection. Study design: In this study, we compared a transcription-mediated-amplification assay (Procleix® HIV-1 Discriminatory Assay, [TMA]) with a branched DNA assay (Bayer Versant HIV-1 RNA 3.0 assay, [bDNA]). Results: After re-testing 1552 samples that were negative for HIV RNA by bDNA, we found one additional positive sample with the TMA assay. Conclusion: Our results suggest that TMA could potentially detect acute HIV infections missed by other technologies.

AB - Background: Very limited data exist on the comparative performance of nucleic acid amplification tests (NATs) for the screening of pooled specimens for acute human immunodeficiency virus (HIV) infection. Study design: In this study, we compared a transcription-mediated-amplification assay (Procleix® HIV-1 Discriminatory Assay, [TMA]) with a branched DNA assay (Bayer Versant HIV-1 RNA 3.0 assay, [bDNA]). Results: After re-testing 1552 samples that were negative for HIV RNA by bDNA, we found one additional positive sample with the TMA assay. Conclusion: Our results suggest that TMA could potentially detect acute HIV infections missed by other technologies.

KW - bDNA

KW - HIV

KW - Pooled testing

KW - TMA

UR - http://www.scopus.com/inward/record.url?scp=34548129582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548129582&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2007.06.004

DO - 10.1016/j.jcv.2007.06.004

M3 - Article

C2 - 17662648

AN - SCOPUS:34548129582

SN - 1386-6532

VL - 40

SP - 68

EP - 70

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

IS - 1

ER -

Performance of a transcription-mediated-amplification HIV-1 RNA assay in pooled specimens

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this